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One Sentence Summary: This manuscript describes a paper-based, multiplexed microfluidic 
assay for rapid, semi-quantitative, visual measurement of AST and ALT in clinical whole blood 
and serum specimens.  
 
Abstract: In developed nations, monitoring for drug-induced liver injury (DILI) via serial 
measurements of serum transaminases (aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT)) in at-risk individuals is standard-of-care. Despite the need, monitoring 
for DILI in resource-limited settings is often limited by expense and logistics, even for patients at 
highest risk.  This manuscript describes a paper-based multiplexed microfluidic assay for rapid, 
semi-quantitative, visual measurement of AST and ALT in a fingerstick specimen. Using clinical 
specimens obtained by venipuncture, we have shown that our assay can, in 15 min, provide 
measurements of AST and ALT in whole blood or serum that allow the user to place those 
values into one of three readout “bins” (<3x upper limit of normal (ULN), 3–5x ULN, and >5x 
ULN, corresponding to TB/HIV treatment guidelines) with >90% accuracy. These data suggest 
that the ultimate point-of-care fingerstick device will have high impact on patient care. 
 
 
 
 
 
 Introduction 
  Blood tests for monitoring the status of the liver are a standard part of medical care in 
developed nations, particularly for individuals who either have underlying liver disease or who 
are taking medications that can cause hepatotoxicity.  Accordingly, US guidelines call for 
baseline and serial monitoring of serum transaminases, AST and ALT, in at-risk individuals 
while on standard therapies for tuberculosis (TB) (1) and/or human immunodeficiency virus 
(HIV) (2).  The overall incidence of clinically relevant hepatotoxicity on TB therapy (typically 
due to the medications isoniazid, rifampin, and/or pyrazinamide) ranges from 2–33%, and risk 
may be increased by multiple factors, such as abnormal baseline transaminases, increasing age, 
pre-existent liver disease (e.g. hepatitis B and/or C), alcohol use, pregnancy, and malnutrition (1, 
3). Hepatotoxicity associated with nevirapine-based antiretroviral therapy, widely used in the 
developing world, is of particular concern; rates of nevirapine-associated hepatotoxicity can 
exceed 13%, depending on underlying risk factors and treatment (2, 4, 5). Simultaneous 
treatment for both TB and HIV further complicates matters, and sometimes generates additive 
risk of hepatotoxicity (6, 7). In practice, however, it is difficult to predict accurately which 
patients on treatment will actually develop hepatotoxicity.  For example, severe idiosyncratic 
drug-induced liver injury has been observed (8) in patients with no obvious predictors for 
isoniazid-associated liver injury who were treated with isoniazid alone for latent TB.  
Monitoring for hepatotoxicity in resource-limited settings is often limited by relative 
expense and logistical and practical concerns, even for patients at highest risk of hepatotoxicity.  
Testing is often done in centralized or regional laboratories in these settings, and obtaining and 
acting on results can be substantially delayed. Many patients have strong negative feelings about 
venipuncture itself, and this aversion can be a barrier to care (9).  Because of these obstacles, in many resource-limited settings patients with TB and/or HIV receive minimal or no monitoring 
during treatment. A low-cost, less invasive, point-of-care (POC) transaminase test would have a 
dramatic impact on patient care in the developing world. 
In order to maintain the advantages of low-cost and user-friendly operation necessary for 
universal access to POC screening, without sacrificing the ability to perform clinically useful 
(and even complex) tests, we (10–15), and others (16–23), have developed microfluidic 
platforms based on paper (broadly defined as thin, porous media).  Paper-based microfluidic 
devices consist of hydrophilic paper channels defined by patterning of hydrophobic barriers (10, 
12, 13) or by cutting (16–20, 23). Using these defined channels, fluid flow can be directed 
towards specific detection zones and operations such as mixing, splitting, and filtration can be 
performed autonomously.  
The advantages of patterned paper devices over traditional POC devices include: i) the 
capacity for high levels of multiplexing, ii) ease of exchanging assays in individual test zones, 
iii) the broad availability of relevant, well-characterized materials and technology at low cost, iv) 
the fact that no power is required, v) the fact that paper is easily chemically modified, vi) the 
availability of techniques to modify and direct flow within microfluidic channels, and in three 
dimensions, without external pumps or instrumentation, and vii) easy portability and 
disposability. Paper microfluidic technology has been reported in several publications focusing 
on the patterning technology (10, 12, 13, 18, 21, 23), fluid behavior (16–19), and potential 
clinical diagnostic applications (11–24). These proof-of-principle studies have demonstrated both 
the ability to conduct clinical chemistry, enzymatic, immunoassay, and ELISA tests on patterned 
paper, visually and quantitatively (latter through the use of camera-enabled cellphones) and the 
viability of both single layer (12, 14, 16–24) and three-dimensional (13) patterned paper devices.  Analytes detected on patterned-paper platforms thus far have included glucose (colorimetric (10-
13, 22) and electrochemical (15)), protein (bovine serum albumin) (12, 23, 24), HIV gp41 
antibody (14), ketones (23), nitrites (23), AST (24), and alkaline phosphatase (24). 
Despite this substantial body of proof-of-concept work, there are no data, to our 
knowledge, evaluating actual clinical specimens using a paper-based microfluidic device, and a 
field-ready clinical test has never been demonstrated.  
Herein, we demonstrate major progress towards the development of a paper-based, POC 
assay for rapid semi-quantitative measurement of AST and ALT in a fingerstick whole blood 
specimen. Ours will be the first actual clinical assay developed using patterned paper technology. 
For highest clinical utility, the device has been optimized for visual color readout in AST and 
ALT ranges (“bins”) that correspond to the cutoffs (<3x ULN, 3–5x ULN, and >5x ULN) 
currently used for clinical management decisions per US TB (1) and HIV treatment guidelines 
(2).  Our data suggest that ultimately, the fingerstick device will have the potential for high 
impact on patient care, particularly in resource-limited settings.  
 
Results  
Design and chemistry of the paper-based transaminase test 
  The paper-based transaminase test is an example of a three-dimensional device made 
from layering patterned paper. To create a layer of patterned paper, we used a wax-based printer 
and a heat source to print hydrophobic barriers into a sheet of paper in order to create 
microfluidic, hydrophilic paths within the paper, through which flow (drawn by wicking) can be 
directed to specific “detection zones.” Layers of patterned paper were stacked to generate 3-D devices by depositing patterned layers of hydrophobic adhesive via screen printing and adhering 
multiple sheets together.  Our postage stamp-sized device (20 x 20 x 0.5 mm) is designed to 
perform two separate tests from a single drop of blood; specifically, one zone measures AST and 
another measures ALT. Additionally, the test contains three control zones to ensure proper 
device performance. Each test zone has a unique environment (pH, buffer, reagents, etc). The 
AST assay chemistry (Supplementary Methods) is based on the sulfonation of methyl green, 
which results in a visual transformation from blue to pink as the dye becomes colorless and the 
pink background color (Rhodamine B) is revealed. The ALT assay chemistry (Supplementary 
Methods) is based on the conversion of l-alanine to pyruvate, the subsequent oxidation of 
pyruvate by pyruvate oxidase, and the utilization by horseradish peroxidase of the liberated 
hydrogen peroxide to generate a red dye through the coupling of 4-amino antipyrine and N,N-
dimethylaminobenzoic acid. 
Our device consists of two layers of similarly patterned paper, a plasma separation 
membrane, and a laminated cover of polyester film to protect the device from the environment 
and limit evaporation (Fig. 1A). A hole in the lamination allows for a fingerstick or pipetted drop 
(30 L) of whole blood (or serum) to be applied to the plasma separation membrane (Fig. 1B); if 
whole blood is applied, blood cells are captured and retained by the plasma separation membrane 
while plasma wicks into the individual “zones” in the first layer of paper below.  In those zones, 
the plasma fluid reconstitutes dried reagents (as required for the zone-specific chemistry) and 
continues to wick to the second layer of paper, where analytes in the plasma react with additional 
dried reagents in each detection zone (Fig. S1) and generate visual colorimetric signals that can 
be interpreted using a visual “read guide” (Fig. 1C).  The assay is read 15 min after “activation” (application of the blood or serum specimen) 
by viewing the test and control zones (Fig. 1B, Fig. 2).  For the ALT and AST test zones, the 
color present in the zone is matched to the gradient of color in the visual “read guide” to obtain a 
result (Fig. 1C). The read guide was generated using device images obtained from a desktop 
scanner and image analysis software (Methods).  The paper-based transaminase test has a 
number of features that provide critical information to the user (Fig. 2). The test has been 
carefully engineered for visual read-out, in that the AST/ALT test zones provide a strong color 
change across the target clinical range (Fig. 1C, Fig. 2A, B). We specifically optimized the 
interpretable ranges for AST and ALT values (i.e. corresponding color readouts in the test zones) 
to correspond to the cutoffs currently used for clinical management decisions per US TB 
treatment guidelines (1).  Accordingly, the results of the test are interpreted as being within one 
of the following three “bins”:  <3x the upper limit of normal (ULN) (0–119 U/L), 3–5x ULN 
(120–200 U/L), or >5x ULN (>200 U/L)(Fig. 1C).  The additional color gradation within each 
bin on the reading guide (Fig. 1C) allows the reader to assess approximately where within the bin 
the result lies, and thus allows semi-quantitative readout.  Additionally, three control zones 
notify the user of insufficient sample volume, hemolysis, or damaged reagents (Fig. 2C–E); each 
zone is interpreted as “valid” or “invalid.”  A result of “invalid” in any of the three control zones 
invalidates the entire device.    
Analytical performance of the prototype device in buffer, whole blood, and serum 
  Linearity of the test was measured by adding known amounts of purified ALT and AST 
to fresh whole blood (Methods), pipetting 30 L of blood onto the device and digitizing the color 
reactions observed after 15 min using a desktop scanner. Image analysis software (ImageJ, NIH) 
was used to translate the resulting color intensities in each scanned zone into quantitative information. Both assays were linear across the target clinical range (40 to 200 U/L), and the 
95% prediction intervals showed that, given a particular ALT or AST value, the range of 
possible color intensities was relatively narrow (Fig. 3). R-squared values of 0.95 and 0.98 were 
measured for the ALT and AST plots, respectively (each datum represents an average of three 
devices).  
Limit of detection (LOD) curves were generated for the AST and ALT assays (Methods) 
and fit to the Hill equation by non-linear regression (14). Color intensity was measured as 
previously described (desktop scanner/ImageJ). Intensity was measured for ALT/AST 
concentrations prepared in buffer spanning several orders of magnitude (N=7 measurements per 
point). The calculated LOD was 53 U/L for the ALT assay and 84 U/L for the AST assay (Fig. 
4).  
To measure repeatability of the paper-based test, color intensity was measured 
(scanner/ImageJ) for simulated clinical samples (commercial serum samples with known 
AST/ALT values, and fresh whole blood samples spiked with AST/ALT (Methods) containing 
low/normal (“Low”) and elevated (“High”)  levels of AST and ALT (Table 1). Ten devices were 
used to measure each sample. Precision was quantified using the coefficient of variation (%CV), 
defined as the standard deviation divided by the mean, for each sample. Values of the CV were < 
10% for both AST and ALT tests in all four conditions (elevated/normal serum/blood)(Table 1).  
Performance of the prototype device in clinical specimens 
  In order to measure the accuracy of the paper-based transaminase test with respect to the 
ability of a reader to place values measured by eye in the correct bin (<3x ULN, 3–5x ULN, or 
>5x ULN), a set of clinical specimens was tested. For these experiments, we tested aliquots (30 L) of paired whole blood and serum specimens that had been drawn (in standard EDTA-
containing and serum-separator tubes, respectively) simultaneously from Beth Israel Deaconess 
Medical Center (BIDMC) patients within the previous 5 h for routine clinical testing, and for 
which results of automated transaminase testing (Methods) of the serum specimen were available 
(BIDMC does not perform transaminase testing on whole blood specimens).  Aliquots (30 L) of 
blood or serum were applied to each device, and the devices were allowed to sit at room 
temperature (range: 21–24 
oC) for 15 min.  Each paper assay was then read visually by three 
independent readers who were blinded to automated results.  The readers independently matched 
test zone colors to the closest color/value found on the read guide (Fig. 1C) and recorded a result 
in U/L (rounded to the nearest 10 U/L ; i.e. 100 U/L  or 110 U/L ). (Of note, some color 
resolution is lost when scanning the devices. The loss in resolution results in conservatively 
calculated LOD values (above). Attempts to distinguish values below the calculated LODs 
visually were allowed, as discernible color changes, observed by eye, made it possible (in 
principle) to discriminate lower values (Fig. 1C).  Importantly, discrimination at these lower 
values does not affect the resulting “bin” placement). 
Results of the paper-based transaminase test for paired whole blood and serum specimens 
were then compared to the results of automated serum transaminase testing as the gold-standard 
(Fig. 5A–D).   Given that EDTA plasma (separated from cells within 8 h of collection at room 
temperature) is an acceptable alternative specimen for testing by the automated assay used at 
BIDMC, it was assumed that gold standard results for the whole blood specimen (i.e. plasma) 
would have been equivalent to gold standard results for the paired serum specimen.  Results for 
the single paper-based assay performed on each whole blood specimen (i.e. 3 results, one per 
reader) were averaged to generate each datum (Fig. 5B, D). For serum specimens, all specimens with sufficient volume remaining after initial testing were stored at 4 ˚C and then blindly retested 
in triplicate (three readers blinded to the original automated results read each of three assays 
performed per specimen) within the subsequent 2.5 weeks and results of all tests performed on 
each serum specimen were then averaged to generate each datum (Fig. 5A, C) (unaveraged raw 
data are presented in Tables S1–S4).   Internal studies at BIDMC have shown that automated 
serum transaminase results are stable in serum refrigerated for at least 2 weeks (data not shown); 
similarly, there was no systematic change in AST or ALT results in either direction (i.e. higher 
or lower) noted on repeat testing of stored serum specimens (data not shown). 
Results of the paper-based assay for each specimen (paired whole blood and serum) were 
compared to the gold-standard serum transaminase results to evaluate “bin placement accuracy” 
(whether the result of the paper-based assay was in the same bin (<3x ULN, 3–5x ULN, or >5x 
ULN, as defined above) as the gold-standard result).  The blue boxes (Fig. 5A-D) encompass 
values for which results of both the paper device and the gold-standard test were in the same bin. 
We calculated bin placement accuracy by determining if each datum met at least one of the 
following criteria: i) the value measured by the paper transaminase test was within the correct 
bin as determined by the automated (true) value, or ii) the value measured by the paper test was 
within 40 U/L of the true value (i.e. between the green and purple lines (Fig. 5A-D)). The second 
criterion accounted for values near the boundaries of the bins, as it was agreed that variations of 
<40 U/L near these boundaries were clinically acceptable as they were unlikely to reflect 
appreciable differences in clinical status, despite potentially changing management if strict 
cutoffs were to be used for decision-making (see Discussion). Results for the paper-based test 
that were neither within the correct bin nor within 40 U/L of the gold-standard result were 
considered inaccurate (red circles, Fig. 5A-D).  It is important to note that samples below the limits of detection (53 and 84 U/L for ALT and AST, respectively) would yield equivalent 
results from the colorimetric test. These threshold values are well within the <3x ULN range and 
no clinical action would be expected for the target patient population.  Because the device is 
meant to detect substantially elevated (>3x ULN) transaminase levels, the assay chemistry is 
tailored to exhibit the greatest color changes between 3x and 5x ULN.  Values well above 5x 
ULN, being out of the linear range, will appear the same on the test and will thus prompt the 
same clinical response (see also Discussion).  Notably, the measuring range for the automated 
assay used at BIDMC is 4–400 U/L (0–10x ULN); higher values must be measured by sample 
dilution. 
Bin placement accuracies are presented in Table 2.  Overall accuracies for the device 
(data for all three bins in aggregate) were above 90% for both AST and ALT in both serum and 
whole blood. Additionally, “per bin” accuracies were calculated by dividing the number of 
correctly binned samples in each bin by the total number of samples in that bin. The data reveal 
that ALT accuracies were higher for serum than for whole blood, particularly in the 3–5x bin 
(92% vs 57%, respectively, p<0.00003). This disparity can be explained by the age of the whole 
blood (2–5 h, i.e. drawn from patient 2–5 h prior) at the time of testing. In early experiments 
(data not shown), we found that whole blood samples began to yield artificially high ALT values 
after aging for >3 h from the time of draw. We believe that this drift in values with age is due to 
the fact that, over time, red blood cells (RBCs) release lactate, which is then converted to 
pyruvate; the excess pyruvate leads to activation of the ALT assay and therefore falsely high 
readings. In the case of serum, RBCs are separated from the serum shortly after draw, preventing 
accumulation of pyruvate in serum. Therefore, accuracies from fresh whole blood (i.e. from a 
fingerstick) are expected to mirror the serum results in this study. This hypothesis has been confirmed using freshly drawn whole blood samples with known amounts of ALT added 
(above), which do not generate falsely high results.  Of note, this effect is not seen in commercial 
assays because these assays measure the kinetic rate of color formation after the native pyruvate 
is consumed during an initial incubation period.  
We further evaluated device performance by Bland-Altman analysis (25).  Specifically, 
we compared the semi-continuous data (reader estimates of actual values, to the nearest 10 U/L, 
obtained using the visual reading guide as described above) to the continuous data obtained by 
gold-standard automated testing.  The goal of this analysis was to obtain a more highly resolved 
assessment of agreement with the gold-standard method, and to explore device bias and 
variability in the target clinical range (defined for this analysis as 40–250 U/L). The data (Fig. 
6A-D) reveal several interesting points: i) A bias to overestimate the ALT whole blood data by 
18 U/L on average is observed (Fig. 6B), likely due to pyruvate generation as described above. 
The 95% limits of agreement, the interval that we expect will contain 95% of paired differences, 
go from –63 U/L to +99 U/L for the ALT whole blood data set. ii) The AST whole blood (Fig. 
6D) plot shows virtually zero bias and 95% limits of agreement from –59 to +62 U/L. iii) For 
serum ALT and AST values, we applied a log transformation to our data because the Bland-
Altman plot of the untransformed data showed an increase in variability of the differences with 
increasing magnitude of measurement (Fig. S3). The log transformed Bland-Altman plots for 
ALT and AST serum successfully removed the relationship between differences and the mean 
(Fig. 6A, C). The data were then back-transformed to give values relating to the ratio of the 
untransformed measurements. Specifically, the paper-based test underestimated ALT serum by 
9% on average and the 95% limits of agreement were between 60% lower and 90% higher for 
ALT serum. After the same transformation, AST serum results reveal that the paper-based test overestimated AST serum by 12% on average and the 95% limits of agreement were between 
63% lower and 100% higher. 
As stated above, differences of ±40 U/L are unlikely to change the course of treatment in 
many clinical situations. Moreover, the differences between color swatches on the read guide are 
each 20–30 U/L and we expect (though cannot easily quantify) that the maximum resolution of 
the device is similarly 20–30 U/L.  We are therefore encouraged by these collective results as 
they suggest clinically acceptable agreement between the semi-quantitative paper test and the 
gold-standard automated assay method.  
Evaluation of analytes with potential for assay interference 
  Studies were performed to assess common or known substances that could potentially 
interfere with ALT and AST assays. Our data suggest that pyruvic acid and ascorbic acid 
interfere with the ALT assay.  Specifically, pyruvate present at levels >2 mM may produce 
falsely elevated results in the ALT assay, and ascorbic acid present at levels >3 mg/dL may 
produce falsely low ALT results.  All of the other substances tested showed no marked 
interference in the ALT and AST assays at clinically relevant levels, including bilirubin (<10 
mg/dL), cholesterol (<500 mg/dL), glucose (<1000 mg/dL), lactate (<200 mg/dL), urea (<100 
mg/dL), creatinine (<15mg/dL), and hemoglobin (<120 mg/dL) (Methods).  These results are 
consistent with our observations that the paper-based transaminase test performed well in the 
specimens from the clinically diverse population tested in this study (which included many 
patients who were critically ill with multi-organ failure and consequently multiple abnormal lab 
values (particularly bilirubin, lactate dehydrogenase, creatinine, and occasionally lipase)). 
 Assay Temperature and Read Time  
  Fluctuations in temperature affect the speed of the test, most likely due to faster 
enzymatic reactions at higher temperatures (>30 
oC). Our data indicate reliable performance of 
the paper-based transaminase test as performed at room temperature (22–30 
oC) and read at 15 
min. In the case of higher temperatures (31–37 
oC), the test should be read at 10 min to obtain 
comparable results (data not shown).   
Effects of blood volume on assay performance  
  Different volumes (15, 20, 25, 30, 40, 50 µL) of blood, serum or buffer specimens with 
different AST/ALT concentrations were evaluated (data not shown). We did not observe that 
excess fluid altered the performance of the test, presumably because the paper device can only 
absorb a finite amount of fluid sample. Our data further show that at least 25–35 µL of sample is 
required for complete activation of the devices. This can be easily monitored in a field setting by 
adding blood until the filter is fully saturated (i.e. an all-red color is observed across the entire 
filter).  
Assay Stability 
  Stability of the paper transaminase test was evaluated by fabricating a single lot of 
devices and packaging them in heat-sealed, foil-lined pouches (10 tests per pouch) containing a 
silica desiccant packet. Pouches were stored at 25 
oC and periodically opened to evaluate the 
devices using buffer standards (Methods). The results suggest that device performance, as 
measured by color intensity of the assays, did not vary by more than 8% after a period of 11 
weeks at which point the study was concluded. This value is less than the %CV measured for the 
assays so the deviation can be attributed to device variability, not degradation. While this timeframe is encouraging, devices may ultimately require two year stability to be viable products 
for the developing world. Future work will include thorough, long-term evaluations of device 
stability, including at elevated temperatures.  
Performance of the device in fingerstick testing 
  We have conducted initial experiments to observe the performance of the device with 
whole blood obtained via fingerstick. In a small study, 10 healthy volunteers used a lancet 
(SurgiLanceTM SLN300) to obtain a droplet (~30 L) of blood from a finger and introduced it 
to the device (Fig. 1B). 10/10 devices were found to fully activate, meaning that all zones were 
wet with plasma, and all controls worked properly. As expected, AST and ALT levels were 
found to be <60 U/L for all volunteers.   
 
 
 
 
 
 
 
 Figures: 
Fig. 1. Schema of the paper-based AST/ALT test design and protocol.  (A) Device design 
(lamination layer, plasma separation membrane, layers of paper).  (B) Use of the device.  A drop 
of whole blood (either a fingerstick specimen or 30 L of a specimen obtained by venipuncture) 
is applied to the back of the device.  Red and white blood cells are filtered out by the plasma 
separation membrane, while plasma wicks to the five detection zones via patterned hydrophobic 
channels in the paper. After 15 min, the AST (top left) and ALT (top right) test zones are 
matched to a color guide (C) to obtain a value in U/L.  Results are interpreted as being within 
one of three “bins” of values:  <3 times (3x) ULN (defined as 40 U/L); 3–5x ULN; or >5x ULN.   
Fig. 2. Detailed schema of the paper-based transaminase test and possible readouts. A schematic 
of test and control zones (prior to receiving a sample) is shown in the center of the figure.  (A) 
AST test zone: low/normal AST values (<80 U/L) result in a dark blue color (left panel), while 
high AST values (>200 U/L) result in a bright pink color (right panel). (B) ALT test zone: 
low/normal ALT values (<60 U/L) result in a yellow color (left panel), while high ALT values 
(>200 U/L) result in a deep red color (right panel). (C) ALT negative control zone: a change 
from white to yellow indicates appropriate device activation (complete wetting of the zone) (left 
panel); in the event of sample hemolysis, the zone becomes orange/red (right panel) and the 
device is read as “invalid.” (D) AST negative control zone: the baseline blue color remains 
unchanged if dye chemistry is functioning properly (left panel), while the zone becomes bright 
pink in the event of non-specific dye reaction (right panel) and the device is read as “invalid.” 
(E) AST positive control zone: the zone changes from blue to pink if AST reagents are functioning properly (left panel), but remains dark blue if either the reagents are not functioning 
or the zone is not activated (right panel), and the device is read as “invalid.”  
 
 
Fig. 3. Plot of color intensity versus concentration of ALT (left panel) or AST (right panel) in 
U/L. Each datum is an average of three measurements (i.e. three separate devices).  Dashed lines 
represent the upper and lower 95% prediction intervals (Methods). 
  
Fig. 4. Limits of detection curves for Aspartate aminotransferase (AST, left) and Alanine  
 
aminotransferase (ALT, right) using the paper-based transaminase test. Calibration plot of the  
 
output signal of the paper-based transaminase test versus the concentration of AST or ALT in the  
 
sample. For AST, the solid line represents a non-linear regression of Hill Equation:  
 
, where Imax= 105.7 , [L50]=260.9 U/L, n=1.72, and R
2=0.99. The error  
 
bars represent one standard deviation ().  For ALT, the solid line represents a non-linear  
 
regression of Hill Equation:  , where Imax= 126.5, [L50]=331.33 U/L,  
 
n=1.04, and R
2=0.96. The error bars represent one standard deviation (). For both assays the  
 
linear portion of the sigmoidal curve ranges approximately within the concentrations of 40-200  
 
U/L.  
  
Fig. 5. Direct comparison of visual transaminase measurements made with the paper-based 
device to measurements made with a standard-of-care automated method.  ALT (A, B) or AST 
(C, D) values in paired serum (A, C) or whole blood (B, D) clinical specimens are plotted 
against values (in U/L) measured in the serum specimen using a gold-standard automated 
method (Roche Modular Analytics System).   In each plot, the blue boxes represent AST or ALT 
“bins” within which values for both the paper-based device and the automated method are within 
the same range, specifically <3X the ULN  (0–119 U/L), 3–5X ULN (120–200 U/L), or >5X 
ULN (>200 U/L). The red line corresponds to the line of equality (paper device measurement = 
automated measurement) and the green and purple lines correspond to plus 40 U/L and minus 40 
U/L from the line of equality, respectively. Points circled in red are samples that were neither in 
the correct bin nor within 40 U/L of the value measured by the gold-standard automated method (see Results). For scaling purposes, X-axis values measured by the Roche system that exceeded 
400 U/L were plotted between 400 and 500 U/L. 
 
 
 
Fig. 6. Bland-Altman analysis of visual transaminase measurements in clinical specimens. (A) 
ALT values in serum (log transformation); (B) ALT values in whole blood; (C) AST values in 
serum (log transformation); (D) AST values in whole blood.  The purple and blue lines represent 
the 95% limits of agreement (Methods). The red line is the line of equality and the green line is 
the average difference of the methods (Methods).  
 
 Tables 
 
 
   Serum Standard  Serum Standard  Whole Blood   Whole Blood  
Level 1   Level 2   Level 1   Level 2  
ALT= 56 U/L 
AST= 69 U/L  
ALT= 128 U/L 
AST= 244 U/L        
ALT= 40 U/L  
AST= 40 U/L  
ALT= 200 U/L  
AST= 200 U/L   
          
Alanine  Color 
Intensity 
           
Aminotransferase 
(ALT) 
Mean ±S.D.  111.0±6.55  120.6±11.2  93.6±4.75  146.5±10.59 
                 
                 
   %CV  5.89  9.28  5.08  7.22 
                 
Aspartate  
 
Aminotransferase 
(AST) 
Color 
Intensity 
           
Mean ±S.D.  62.6±5.52  151.1±7.60  65.3±5.24  168.5±4.45 
              
              
%CV  8.82  5.03  8.01  2.64 
              
Table 1.   Repeatability of the paper transaminase test as measured by % coefficient of 
variation (CV). Samples were prepared as described (Methods) and each was tested with 
10 devices.  Color intensity was measured by scanning the devices using a desktop scanner 
and subsequently analyzing images of individual zones using ImageJ software (red and 
green channels were used for Aspartate aminotransferase (AST) and Alanine 
aminotransferase (ALT), respectively). %CV’s were calculated by dividing the standard 
deviation by the mean intensity (N=10 devices per specimen with a given value). 
  
 
 
 
 
 
 
 
Test  Specimen  Bin (X = 40 
U/L = ULN) 
No. of 
Samples in 
bin 
No. 
Correctly 
Placed 
“Per Bin ” 
Accuracy  Overall 
Accuracy 
ALT 
Serum 
<3X  89  88  99%   
3–5X  12  11  92%  95%  (±4%) 
>5X  19  15  79%   
Blood 
<3X  70  66  94%   
3–5X  7  4  57%  90%  (±6%) 
>5X  11  9  82%   
AST 
Serum 
<3X  88  85  97%   
3–5X  26  18  69%  91%  (±5%) 
>5X  14  14  100%   
Blood 
<3X  69  68  99%   
3–5X  17  13  76%  94%  (±5%) 
>5X  8  7  88%   
Table 2. Bin placement accuracies for visual measurements in clinical specimens made 
using the paper-based transaminase test. 95% confidence intervals around the overall 
accuracy estimates are shown in parentheses. Discussion  
  We have demonstrated that we can accurately measure transaminases in whole blood and 
serum using a simple and very inexpensive paper-based assay that can be read by eye within 
minutes.  Our test performed well, even in specimens that were obtained from critically ill 
patients with multiple derangements in other analytes, and that were up to 5h old at the time of 
testing. Variability, as measured by %CV, was found to be less than 10% for both assays using 
blood and serum samples. The experiments presented here have firmly established proof-of-
concept and clinical relevance and will allow us to move into clinical field studies to evaluate the 
performance of our device in real time using fingerstick blood specimens from those patients for 
whom we see the device having highest utility, including those with TB, HIV, Hepatitis B, and 
Hepatitis C.   
When sufficient resources are available, standard-of-care transaminase testing typically 
involves collecting a whole blood specimen by venipuncture, transporting the specimen to a 
central laboratory, centrifuging to separate serum, and testing the serum on a large automated 
platform.  Such systems are impractically expensive for routine use in developing countries and 
require highly trained technicians for testing and maintenance.  Moreover, the need to perform 
the testing in a central laboratory can considerably delay acquisition and dissemination of results, 
even if access to testing is available.  In some resource-limited settings, it is not uncommon for 
tubes to get lost en route to the central laboratory, and transaminase results can sometimes take 
weeks or even months to return.   
Manufacturing costs are dependent on several key variables, including location, making 
them difficult to calculate accurately a priori.  We anticipate, however, that our device can 
ultimately be produced at a very low cost–on the order of a few pennies per test (Table S5).  Two FDA-approved devices do exist that could potentially be used for rapid POC testing, but, for 
both, utility for the resource-limited setting is limited by expense.  The Roche Refletron Plus 
device requires venous blood draw, relies on complex electronics and electricity/battery, and is 
expensive (approximately $6,000 for the reader and an additional $4 per test.)  Another device, 
the Cholestech LDX, is capable of using fingerstick samples, but the reader and tests are 
similarly expensive (approximately $3,000/$4, respectively).  
Our test has been optimized for detection of AST and ALT values >3x ULN, in light of 
guidelines (e.g. for TB treatment (1)) that place great emphasis on the 3x ULN and 5x ULN 
cutoffs (in concert with symptoms of hepatotoxicity) for making management decisions. While 
we hope to have sufficient resolution in the 3–5x range to allow highly accurate bin placement, 
we also believe that our test could have great benefit as a “rule-out” or “triage” test.  
Specifically, if AST or ALT was observed to be <3x ULN on routine screening with the POC 
test, no further testing would be indicated; if values on the POC test were >3x ULN, the patient 
could proceed to quantitative testing by venipuncture/automated method. Such use would save 
valuable clinical resources and time, while still making triage testing available in remote areas. 
The work presented here indicates that our bin placement accuracies for the <3x ULN bin are 
near 100%.  Our results for ALT (whole blood) indicate that no specimens with gold-standard 
ALT values >120 U/L were read by the paper-based test as <120 U/L (Fig. 5B). For AST (whole 
blood), a small number of samples with gold-standard AST values >120 U/L were read by the 
paper-based test as <120 U/L (Fig. 5D), and this is a focus of current experiments. Importantly, 
there were no specimens that had gold-standard AST or ALT values >5x ULN and were read as 
<3x ULN (Fig. 5) (TB treatment guidelines (1), for example, recommend that patients with levels >5x ULN stop their TB medications, even if asymptomatic).  Performance of the device at 
the 3x ULN cutoff will be closely examined as we move into real-time fingerstick testing. 
We are currently working on a number of enhancements to the test, which include: i) a 
telemedicine application whereby the colorimetric results of the test could be recognized and 
quantified via smartphone (facilitating increased resolution of results and ease of results 
documentation/transmission, and obviating any concerns about color-blind users); ii) the addition 
of other zones/features to indicate proper device performance and enhance user interaction, and 
iii) large-scale manufacturing methods and techniques, such as robotic spotting of reagents, to 
improve throughput and precision.   
Hepatotoxicity is a major adverse event associated with both anti-tuberculous and anti-
retroviral therapy, and monitoring for drug-induced liver injury (DILI) is accordingly a major 
priority in the care of these patients.  Moreover, there are other important and common global 
conditions (such as epilepsy) for which treatment can be associated with substantial 
hepatotoxicity. We anticipate that our device will dramatically simplify and reduce the cost of 
detection and monitoring progression of DILI, making extremely inexpensive, minimally 
invasive, and accurate transaminase testing available at POC for all who need it and thus 
providing  distinct advantages over standard-of-care automated methods using venipuncture.  
Conceivably, our fingerstick test could also improve treatment adherence (9).   Finally, 
successful development of this novel platform will facilitate the development of similar novel 
POC clinical assays for monitoring other clinically important analytes.   
   
 Materials and Methods 
Device fabrication 
  Device patterns were designed using Adobe Illustrator CS3. The pattern consisted of 12 
rows of 9 devices for a total of 108 devices per sheet (Fig. S2). Whatman No. 1 chromatography 
paper (8.5x11”) was fed into a laser printer (HP Color Laserjet 4520) and nine 0.85x14 cm 
yellow (Y=100% on CMYK scale) stripes were printed on the sheet. A wax pattern (Fig. S2) for 
the top layer (layer from which the device is read) was printed onto this sheet using a Xerox 
8560DN printer such that the wax pattern was printed on the opposite side of the paper as the 
yellow stripe and that the yellow stripes only covered the back face of the ALT test zones and 
ALT negative controls in each column (i.e. did not cover the back face of the AST test or AST 
control zones). The sheet was heated in a gravity convection oven at 150 
oC for 30 s. A wax 
pattern for the bottom layer (layer in contact with filters) was printed onto Whatman No. 1 
Chromatography paper using a Xerox 8560DN printer and heated in the oven at 150 
oC for 30 s. 
This layer did not have a yellow stripe on the reverse side of the paper. A pressure-sensitive 
adhesive (UNITAK 131, Henkel) was applied to the back of the top layer by screen printing such 
that the 5 active zones of the device did not receive adhesive but the remaining areas did. The 
layer was placed in a gravity convection oven set to 70 
oC for 15 min. This screen-printing and 
heating process was repeated on the back of the bottom layer. The sheets were then taped to a 
plastic frame in order to spot reagents. Details of the reagents used in each zone (ALT and AST 
test zones, and three control zones) are provided in Supplementary Methods; zones were spotted 
using a micropipette according to Fig. S1. Where multiple reagent spots were required (ALT test 
zone, AST positive control zone), the first spot was allowed to dry completely (air dry at room 
temperature) before applying the second. A hole-puncher was used to punch alignment holes (preprinted on the corners of each sheet) in both device layers. The layers were aligned and 
laminated using a benchtop laminator (Apache AL13P) at a speed of 2 ft/min. Cold lamination 
(Fellowes self-adhesive laminate sheets) was then placed on the front face of the sheet of 
devices. An array consisting of 108 holes (each hole aligned with the center of a device), each 
with a diameter of 7mm was cut on a second sheet of laminate using a knife plotter (Craftrobo 
Silhouette CC330L-20 SD) and placed on a bench adhesive side up. 1 cm pre-cut discs of Pall 
Vivid GX plasma separation membrane were then centered over the holes in the laminate sheet 
in such a way that the rough side of the membrane was in contact with the adhesive. The cut 
laminate with adhered filters was then aligned and laminated to the back of the device sheet stack 
such that each filter covered all 5 zones of the device. Finally, the entire stack was laminated to 
ensure good contact between all layers. Individual devices were then cut by hand and stored in 
heat-sealed foil-lined bags containing 1 packet of silica desiccant (Sigma) with 10 devices / bag. 
Read Guide 
  The read guide (Fig. 1C) was generated by adding known amounts (as provided by the 
vendor) of AST and ALT (Lee bio) to fresh whole blood (drawn by venipuncture, baseline 
AST/ALT 24/22 U/L) to generate final concentrations of 40, 60, 80, 100, 120, 150, 180, 200, 
250, 300, and 400 U/L. 30 L of sample were added to each of 3 devices for all concentrations. 
After 15 min, the devices were scanned using a desktop scanner (Canon). Experiments were 
performed at room temperature (25 
oC). Images were analyzed using Adobe Illustrator CS3 to 
generate color swatches with the appropriate CMYK values. The read guide was printed and 
laminated between two Fellowes self-adhesive laminate sheets using a benchtop laminator 
(Apache AL13P). 
 Linearity Studies 
  For linearity studies, measured amounts of AST and ALT (Lee Bio) were added to fresh 
whole blood (drawn by venipuncture, baseline AST/ALT 24/22 U/L) to generate final 
concentrations of 40, 60, 80, 100, 120, 150, 180, 200, 250, 300, and 400 U/L. 30 L of sample 
were added to each of 3 devices for all concentrations. After 15 minutes, the devices were 
scanned using a desktop scanner (Canon). Experiments were performed at room temperature (25 
oC). Images were analyzed using ImageJ software (NIH) to obtain color intensity values for each 
zone. ALT data were quantified using the green channel and final values were normalized by 
subtracting from 255 (255 is the maximum color intensity value in the RGB color model and this 
normalization allows for a positive correlation between ALT values and color intensity in the 
green channel). AST data were quantified using the red channel without normalization. 95% 
prediction intervals were calculated using an excel macro, PredInt.xls, version 8.3. 
 
Limit of Detection Studies 
  For limit of detection studies, measured amounts of AST and ALT (Lee Bio) were added 
to artificial blood plasma buffer to generate final concentrations of 0.1, 1, 5, 10, 20, 40, 80, 120, 
160, 200, 400, 1000, and 10,000 U/L. 30 L of sample were added to each of 7 devices for all 
concentrations. After 15 minutes, the devices were scanned using a desktop scanner (Canon). 
Experiments were performed at room temperature (25 
oC). Images were analyzed using ImageJ 
software (NIH) to obtain color intensity values for each zone. ALT data were quantified using 
the green channel and final values were normalized by subtracting from 255. AST data were 
quantified using the red channel without normalization.  
 Repeatability Studies 
  For repeatability studies, commercial serum standards containing known (as measured by 
the vendor) AST/ALT values were purchased from Pointe Scientific.  Two levels were used for 
these studies: Level I standards contained 69/56 U/L of AST/ALT respectively and Level II 
standards contained 244/128 U/L of AST/ALT respectively. Whole blood samples were also 
prepared by adding known amounts of AST and ALT (Lee Bio) to fresh whole blood (drawn by 
venipuncture, baseline AST/ALT 24/22 U/L) to generate final concentrations of 40 (Level I) and 
200 U/L (Level II). A total of four samples were prepared for testing (Level I/II serum samples 
and Level I/II whole blood samples).  30 L of sample were added to each of 10 devices for all 
concentrations. Experiments were performed at room temperature (25 
oC).  After 15 minutes, the 
devices were scanned using a desktop scanner (Canon). Images were analyzed using ImageJ 
software (NIH) to obtain color intensity values for each zone. ALT data were quantified using 
the green channel and final values were normalized by subtracting from 255. AST data were 
quantified using the red channel without normalization.  
 
Stability Studies 
  For stability studies, approximately 100 devices were fabricated and stored in foil-lined 
pouches (Plastic Bags For You), 10 tests to a pouch, each containing 1 packet of silica desiccant 
(Sigma). The pouches were sealed using a Hualian heat sealer. The pouches were stored at 25
oC 
and were tested at 0, 4, 8, 14, 21, 33, 42, 63, and 77 days using buffer standards prepared in 
artificial blood plasma buffer. Buffer standards were generated by adding measured amounts of 
AST and ALT (Lee bio) to artificial blood plasma buffer to generate final concentrations of 40 
and 200 U/L. 30 L of sample were added to each device for all concentrations. After 15 minutes, the devices were scanned using a desktop scanner (Canon). Experiments were 
performed at room temperature (25 
oC). Images were analyzed using ImageJ software (NIH) to 
obtain color intensity values for each zone. ALT data were quantified using the green channel 
and final values were normalized by subtracting from 255. AST data were quantified using the 
red channel without normalization. 
 
Experiments to evaluate potential interfering factors 
  Human serum samples with baseline AST/ALT levels measured by the supplier were 
obtained from Valley Biomedicals Inc. Purified ALT/AST (Lee bio) was then added to generate 
final levels of approximately 40 U/L (normal, representing 1-3X ULN bin), 150 U/L (elevated, 
representing 3-5X ULN bin) and 400 U/L (highly elevated, representing >5X ULN bin). Stock 
solutions of potential interfering reagents were prepared and added to the above three types of 
ALT/AST serum samples at different final concentrations.  
 
Collection and testing of clinical specimens 
  The protocol for access to discarded clinical specimens and associated clinical data was 
approved by the Investigational Review Board of Beth Israel Deaconess Medical Center 
(BIDMC).  Routine clinical transaminase testing (AST/ALT) at BIDMC was performed on 
serum specimens by the BIDMC clinical chemistry laboratory using a Roche Modular Analytics 
System (P800 spectrophotometer module).   Paired whole blood (drawn in lavender–top EDTA 
tube) and serum (drawn in green–top heparin serum separator tube) specimens that were less than 5 
hours old (age defined as time since venipuncture) were identified by searching electronically for 
reported serum AST and ALT results that spanned the clinical range and then confirming that a 
whole blood specimen had been drawn from that patient at the same time.  200 microliter aliquots of each specimen were removed and these aliquots were de–identified.   30 microliter aliquots of each 
de–identified specimen were applied to individual devices by micropipette.  15 minutes after 
application, results were read by eye in silence by three independent readers who were blinded to 
the results of automated transaminase testing of the serum specimens.  Results were interpreted by 
comparing color changes in the ALT and AST test zones to the read guide (Fig. 1C) and results 
were recorded as values rounded to the nearest 10 U/L. Control zone colors were checked according 
to Fig. 2 to confirm proper device function.  Whole blood specimens were discarded after initial 
testing; serum specimens were stored at 4 
oC for repeat testing (Results). Fingerstick specimens 
were obtained from volunteers at Diagnostics For All, all of whom provided verbal consent after 
hearing a detailed explanation of the test procedure.   
 
Bland–Altman Analysis 
  Bland–Altman analysis was conducted for values ranging from 0–275 U/L for each data 
set (ALT whole blood, ALT serum, AST whole blood, AST serum). Values greater than 275 U/L 
were removed from this analysis because the test signal saturates above this threshold. Such 
values resulted in artificially high 95% limits of agreement. Furthermore, the clinical action is 
the same for all values in this bin. For example, a value of 2000 U/L(as measured by the Roche 
instrument) would saturate the paper test signal and yield a visual value of 400 U/L. The D value 
(defined below) for this data point would be –1600 U/L
 despite correctly identifying the sample 
in the >5X ULN bin. 
 
Bland–Altman analysis was conducted by calculating the following: 
 Di = (Pi–Ri)  
 
Where Di is the difference between a value measured by the Paper transaminase test (Pi) and the 
Gold–Standard Roche Instrument (Ri). A scatter plot was generated using Microsoft Excel 
consisting of (Mi, Di) for each data point in the series where Mi is the average of Pi and Ri.  
The mean difference (U) was calculated according to the following equation: 
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Where U is the average difference, Di  is the difference between the methods for a given point 
and n is the number of samples. U was then plotted as a straight line on the scatter plot as the 
equation Y=U.
 The standard deviation (Sd) of Di  was calculated according to the following 
equation:
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95% limits of agreement were calculated according to the equations: 
L1 = U + (1.96)Sd where L1 is the upper limit of agreement, U is the mean difference and Sd is the 
standard deviation of Di. L2 = U – (1.96)Sd where L2 is the lower limit of agreement, U is the 
mean difference and Sd is the standard deviation of Di. L1 and L2 were then plotted as straight 
lines on the scatter plot as the equations Y=L1 and Y=L2.The line of equality was plotted as 
straight line according to the equation (Y=0)  
  Log transformation was applied according to the methods described by Bland and Altman 
(18). Briefly, Y axis values were obtained by taking the natural logarithm (Ln) of the Paper test 
and Roche values and subtracting Ln Roche from Ln Paper test. X axis values were obtained by 
averaging Ln Paper test and Ln Roche values. 95% limits of agreement were calculated as 
described above only using the log transformed values. Limits of agreement were then back 
transformed with an antilog function (e
x). 
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Fig. S1. Locations of spotted reagent solutions for ALT and AST assays. 
Fig. S2. Device pattern generated in Adobe Illustrator used for wax printing of device sheets on 
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Fig. S3. Bland-Altman analysis of visual transaminase measurements in clinical serum 
specimens prior to the log transformation done for Figure 5.   
Table S1. ALT whole blood raw data 
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Table S3. ALT serum raw data 
Table S4. AST serum raw data 
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 Supplementary Methods: 
 
Reagents for ALT Assay 
Alanine Solution - A solution containing 1M L-alanine (Sigma Aldrich), 30 mM ketoglutaric 
acid (Sigma Aldrich), 2 mM KH2PO4(Sigma Aldrich), 20 mM MgCl2 (Sigma Aldrich), 2 mM 
Thiamine Pyrophosphate (MP Biosciences),  2 mM of 4-aminoantipyrine (Sigma Aldrich) and 
25 U/mL (0.1 mg/mL) Horseradish Peroxidase (HRP) (Sigma Aldrich) was prepared  in 200 mM 
Tris buffer (pH=7.4). 
DABA Solution – A solution containing 10 wt% PEG (MW = 35,000 g/mol, Sigma Aldrich) and 
10 mM Dimethylaminobenzoic acid was prepared in DI water. 
Pyruvate Oxidase – A solution containing 100 U/mL of Pyruvate Oxidase (MP Biosciences, 
EMD) was prepared in 200mM Tris buffer pH=7.4. 
PEG Solution - A solution containing 5wt% PEG (MW = 35,000 g/mol, Sigma Aldrich) was 
prepared in DI water. 
 
Reagents for AST Assay 
AST Dye Solution- A solution containing 0.5% Methyl Green, 0.05% Rhodamine B,0.025% 
Triton X 100, 1% PVA (13,000-23,000 g/mol) was prepared in DI water. 
CSA Solution – A solution containing 171.1 mg CSA (Sigma Aldrich), 14.6 mg ketoglutaric 
acid and 10µL of 200mM EDTA solution was prepared in 1 mL of 40 mM Phosphate Buffer and 
the pH was adjusted to 8.0. AST Positive Control Solution (200KU/L AST solution, 5%PEG, in 1X PBS) – A solution 
was prepared containing 5% PEG (MW = 35,000 g/mol, Sigma Aldrich) in 1X PBS and 6.17 µL 
AST (5177 U/mL, MP Biosciences) were added to make 200 kU/L AST solution.  
 
Artificial Blood Plasma Buffer – A solution containing 84% NaCl, 4% NaHCO3, 2% KCl, 2% 
Na2HPO4•3H2O, 3% MgCl2•6H2O, 3% CaCl2, 1% Na2SO4 was prepared in DI water and the pH 
was adjusted to 7.4.  
 
Supplementary Figures: 
 
 
 
 
 
 
 
 
 
 
 
 
   
Fig. S1.  Locations of spotted reagent solutions for ALT and AST assays. Two layers of patterned paper 
are used in the paper transaminase test, one in which the back side is directly in contact with the filter 
membrane (A), and one from which the results are read (B). 
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Fig. S2.  Device pattern generated in Adobe Illustrator used for wax printing of device sheets on 
paper. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S3.  Bland-Altman analysis of visual transaminase measurements in clinical serum specimens 
prior to the log transformation done for Fig. 6.  Alanine aminotransferase (ALT) and Aspartate 
aminotransferase (AST) levels were measured in serum specimens with the paper-based device, and 
compared to ALT/AST results measured in the serum specimens by a gold-standard automated 
method (Roche, Methods).   For each of the data points shown, the difference between ALT or AST 
levels measured by the two methods was plotted on the y axis, vs the average value of the two 
methods on the x axis. ALT values in serum (top); AST values in serum (bottom).  The purple and 
blue lines represent the 95% limits of agreement (Methods). The red line is the line of equality and 
the green line is the average difference of the methods (Methods).  
 
 Supplementary Tables: 
 
 
Roche Analyzer 
Value (U/L) 
Paper Test 
Value Reader 
1 (U/L) 
Paper Test 
Value 
Reader 2 (U/L) 
Paper  Test  
Value 
Reader 3 
(U/L) 
Paper Test Value 
Average 
(U/L) 
6  40  40  20  33 
8  40  40  25  35 
8  80  80  80  80 
9  100  110  110  107 
12  40  40  40  40 
14  50  60  40  50 
15  90  70  90  83 
16  60  40  60  53 
17  50  60  40  50 
18  60  80  60  67 
19  40  40  60  47 
21  80  60  80  73 
21  100  100  110  103 
24  100  120  110  110 
26  60  60  80  67 
28  60  60  80  67 
28  70  100  80  83 
29  60  40  60  53 
30  40  40  40  40 
32  40  40  60  47 
33  80  60  100  80 
37  60  40  60  53 
38  80  80  80  80 
39  70  40  80  63 
40  80  100  110  97 
40  100  100  100  100 
42  40  20  60  40 
42  60  40  80  60 
42  80  80  80  80 
46  120  120  150  130 
47  60  60  60  60 
47  60  80  60  67 
50  60  50  80  63 
50  100  80  60  80 
51  120  100  120  113 
53  40  40  40  40 
53  110  110  100  107 
55  100  90  110  100 
56  60  40  80  60 
56  60  80  80  73 
58  120  110  130  120 
65  80  80  110  90 
66  100  80  100  93  
 
  Table S1. ALT whole blood raw data 
 
 
 
68  100  100  100  100 
68  120  100  100  107 
70  80  80  90  83 
74  100  100  110  103 
74  100  120  140  120 
75  40  20  40  33 
78  100  80  100  93 
79  150  150  150  150 
80  60  80  100  80 
84  60  60  100  73 
84  110  120  100  110 
85  100  110  120  110 
99  120  100  130  117 
101  60  60  60  60 
104  120  120  160  133 
105  60  70  110  80 
105  130  130  160  140 
106  60  60  60  60 
107  40  40  40  40 
108  40  40  60  47 
108  100  100  110  103 
110  130  120  150  133 
115  150  160  130  147 
117  150  160  180  163 
118  200  250  190  213 
124  250  200  200  217 
129  130  140  130  133 
147  200  220  250  223 
156  250  250  250  250 
170  180  200  210  197 
171  150  160  160  157 
188  160  160  160  160 
210  200  220  200  207 
220  180  150  120  150 
232  250  250  250  250 
249  250  250  250  250 
266  180  160  200  180 
350  400  400  400  400 
361  250  250  300  267 
398  400  400  400  400 
400  400  400  400  400 
450  400  400  400  400 
470  400  400  400  400 Roche 
Analyzer 
Value (U/L) 
Paper Test 
Value Reader 1  
(U/L) 
Paper Test Value 
Reader 2 (U/L) 
Paper  Test  
Value 
Reader 3 
(U/L) 
Paper Test Value 
Average 
(U/L) 
11  40  40  60  47 
14  40  40  40  40 
16  40  60  40  47 
17  40  70  50  53 
21  40  40  60  47 
21  40  40  40  40 
24  60  60  60  60 
28  40  40  40  40 
28  40  60  40  47 
28  80  40  40  53 
29  40  40  60  47 
30  80  80  80  80 
34  60  40  60  53 
34  40  40  30  37 
34  40  50  40  43 
36  40  60  70  57 
37  60  60  40  53 
40  40  40  40  40 
40  40  40  40  40 
41  60  90  90  80 
41  40  60  40  47 
42  60  80  80  73 
44  40  40  40  40 
44  40  40  60  47 
45  60  60  60  60 
46  80  60  40  60 
47  40  40  40  40 
47  100  100  90  97 
48  90  80  60  77 
49  60  40  40  47 
49  70  40  80  63 
49  80  60  60  67 
49  80  80  100  87 
53  60  40  80  60 
53  60  30  90  60 
54  80  70  60  70 
54  100  100  95  98 
55  40  80  60  60 
56  40  40  60  47 
58  80  80  90  83 
59  60  60  40  53 
61  60  40  90  63 
61  80  90  80  83 
63  60  60  60  60 
66  120  100  120  113 
66  80  80  60  73 68  80  40  60  60 
70  100  100  100  100 
70  90  80  110  93 
71  60  80  60  67 
74  40  40  40  40 
76  90  90  100  93 
79  60  80  80  73 
80  90  90  90  90 
80  80  90  90  87 
82  90  80  100  90 
90  180  150  150  160 
96  110  90  100  100 
97  60  80  80  73 
100  80  60  90  77 
101  80  60  50  63 
102  80  90  60  77 
103  60  80  70  70 
103  100  100  110  103 
111  110  120  120  117 
112  110  120  100  110 
114  100  90  90  93 
117  60  60  80  67 
119  100  90  100  97 
120  150  150  130  143 
123  80  80  60  73 
125  100  100  80  93 
133  150  130  120  133 
134  100  100  100  100 
138  100  100  70  90 
147  130  200  180  170 
155  180  140  110  143 
155  150  120  140  137 
160  180  180  130  163 
163  180  200  180  187 
166  130  140  130  133 
166  120  100  90  103 
168  180  250  180  203 
173  120  120  120  120 
176  130  130  140  133 
181  130  150  130  137 
194  300  250  300  283 
204  200  300  200  233 
218  300  250  300  283 
226  180  150  180  170 
350  400  400  400  400 
396  400  400  300  367 
450  400  400  400  400 
490  400  400  400  400  
 
Table S2. AST whole blood raw data 
 
 
   Paper Test A (U/L)  Paper Test B (U/L)  Paper Test C (U/L)  Paper Test D (U/L)   
 
Roche 
Analyzer 
Value  
(U/L) 
R1   R2   R3   R1   R2   R3 
 
R1   R2   R3   R1   R2   R3  Average 
Paper Test 
Value (U/L) 
6  40  40  40                    40 
8  40  40  40                    40 
9  40  40  40                    40 
12  30  40  40  40  40  40  40  40  60  40  40  60  43 
14  20  40  40  40  40  40  40  40  40  40  40  40  38 
15  40  40  40                    40 
16  60  50  60                    57 
17  40  40  40                    40 
18  40  40  40  40  40  60  40  40  60  40  60  60  47 
19  40  40  40  40  40  60  40  40  60  40  40  60  45 
21  60  40  40                    47 
21  40  40  40                    40 
23  80  90  80  80  100  80  100  100  100  inv  inv  inv  90 
24  40  40  40  40  40  60  40  60  60  40  60  60  48 
24  40  40  40  40  40  40  40  40  40  40  40  40  40 
24  40  20  40                    33 
26  40  40  40                    40 
27  40  10  40                    30 
27  60  40  60  60  40  60  60  40  60        53 
28  40  40  40  40  40  40  40  40  40  40  40  40  40 
28  60  60  60                    60 
28  80  60  80                    73 
29  40  40  40                    40 
31  40  20  40  60  80  80  60  80  80  60  80  80  63 
32  40  40  40                    40 
32  80  60  80                    73 
33  40  40  40  40  40  60  40  60  60  40  60  60  48 
33  40  40  60  40  40  60  40  40  60        46 
34  40  60  40                    47 
34  40  40  40  40  40  40  40  40  40        40 
37  40  60  60  40  40  60  40  40  60  40  40  60  48 
38  20  40  40  40  40  40  40  40  40  40  40  40  38 
39  80  60  60                    67 
40  40  40  40                    40 
40  60  40  60                    53 
40  60  80  80                    73 
41  40  40  30                    37 
510  400  400  400  400 42  40  40  40  40  40  40  40  40  40  40  40  40  40 
42  40  40  40  40  40  40  40  40  40  40  40  40  40 
42  40  60  60  50  40  40  40  40  40  60  40  60  48 
45  60  40  40  60  60  60  60  40  60        53 
46  60  80  80                    73 
47  60  60  80  40  60  60  40  60  60  40  60  60  57 
47  40  40  40                    40 
47  40  40  60                    47 
50  40  80  80  60  60  60  60  40  60  60  40  60  58 
50  110  90  100                    100 
51  100  90  100                    97 
53  40  60  100  40  40  60  40  40  60  40  40  60  52 
53  20  40  40                    33 
55  100  100  100                    100 
56  40  60  40  40  40  60  60  60  80  50  40  60  53 
56  40  60  40  40  40  40  40  60  40  40  40  40  43 
58  100  80  90                    90 
60  80  80  80                    80 
65  40  20  40  80  80  60  80  80  60  70  80  60  63 
66  80  80  80  60  40  60  60  60  80  60  60  80  67 
68  20  40  40  60  40  60  60  40  60  60  40  60  48 
68  60  80  80                    73 
70  40  70  60                    57 
74  90  60  80  80  80  80  80  60  80  80  40  60  73 
74  100  100  160                    120 
75  40  20  40  40  20  40  40  20  40  40  20  40  33 
78  60  60  60  60  60  60  60  40  60  60  40  60  57 
79  100  110  120  60  80  80  60  80  80  60  80  60  81 
79  60  60  60  60  60  70  60  60  80        63 
80  110  60  80  40  20  40  60  40  40  60  60  60  56 
80  40  40  40  40  40  40  40  40  40        40 
81  80  70  110  90  120  110  100  130  120  90  120  110  104 
84  80  100  100  80  100  100  80  100  100  60  100  100  92 
84  80  80  100                    87 
84  60  60  100                    73 
85  80  80  120  80  130  120  90  130  120  80  130  120  107 
85  120  80  80  100  80  80  100  80  80        88 
89  70  100  80  70  90  80  70  80  80        80 
99  130  80  110  100  130  120  100  120  100  80  120  100  108 
101  60  60  60  40  20  40  40  20  40  40  20  40  40 
104  80  60  inv  70  80  100  70  80  100  70  80  100  81 
104  40  40  40  40  40  40  40  40  40        40 
105  60  80  100  60  100  100  80  100  100  80  100  80  87 
105  120  130  160  80  100  100  100  100  100  100  100  100  108 
106  20  40  60                    40 
107  40  40  60  40  40  40  40  40  60  50  40  60  46 
107  100  90  130  100  100  130  100  80  130        106 
108  60  80  100  80  100  120  40  40  120  60  100  120  85 108  40  40  30                    37 
110  90  90  130  80  100  100  60  80  100  60  80  100  89 
115  40  50  80  80  120  120  100  130  120  100  130  120  99 
 
117  120  120  160                    133 
118  180  140  180  120  180  160  150  180  180  100  160  150  157 
122  110  100  110  120  100  120  120  100  120        111 
122  100  100  110  120  100  120  100  100  100        105 
124  200  180  200                    193 
124  120  120  100  120  120  100  120  120  120        115 
128  120  120  100  120  110  100  100  100  80        105 
129  110  100  110                    107 
147  120  120  120  60  80  80  120  150  120  120  120  120  111 
156  110  130  160                    133 
170  200  180  180                    187 
171  100  100  130  100  120  120  80  120  110  inv  inv  inv  109 
179  100  140  130  100  130  130  100  130  130        121 
188  130.
00 
120.00  130.00                    127 
210  250  250  200                    233 
220  150  150  200  180  200  200  180  200  200  250  200  200  193 
232  400  400  250                    350 
241  120  120  130  120  120  150  120  120  130        125 
249  250  250  200  180  200  200  200  200  200  250  200  200  211 
255  130  130  170  120  180  200  100  160  160  150  200  200  158 
266  120  110  180  250  250  250  250  250  200  inv  inv  inv  207 
316  200  200  180  180  190  150  200  190  180        185 
316  250  200  190  250  200  200  250  180  190        212 
318  200  200  140  250  250  160  200  200  140        193 
361  250  250  300                    267 
398  250  250  250                    250 
400  400  400  400  250  200  250  300  250  250  300  250  250  292 
419  200  250  250  250  250  250  250  250  250        244 
423  300  250  200  250  200  200  300  300  250        250 
425  400  400  400  400  400  400  400  400  400  inv  inv  inv  400 
450  400  400  400  250  250  250  250  250  250  200  250  250  283 
450  400  400  250  250  400  400  200  400  200  250  400  400  329 
470  400  400  400                    400 
 
Table S3. ALT serum raw data. R1, R2, and R3 refer to Reader 1, Reader 2, and Reader 3, 
respectively. Paper Test A-D refers to 4 independent tests used to measure the same sample. 
Blank cells indicate that an insufficient volume of serum was available for all repeats. Inv = 
result was invalid due to sample hemolysis. 
  
   Paper Test A (U/L )  Paper Test B (U/L)  Paper Test C (U/L)  Paper Test D (U/L)   
 
Roche 
Analyzer Value  
(U/L) 
R1   R2   R3   R1   R2   R3   R1   R2   R3   R1   R2   R3   Average Paper 
Test Value 
(U/L) 
11  40  70  60                             57 
14  30  40  40  40  40  60  40  40  40  40  40  40  41 
16  70  80  60                             70 
17  40  40  40                             40 
21  40  40  40                             40 
21  40  40  40                             40 
23  60  80  60  60  40  40  60  40  40  inv  inv  inv  53 
24  60  40  60  40  40  40  40  40  40  40  40  40  43 
25  40  40  40  40  40  40  60  40  40           42 
26  40  40  40  40  40  40  40  40  80           44 
28  60  60  40  40  40  40  40  40  40  40  40  40  43 
28  40  40  40  40  40  40  40  40  40  40  40  40  40 
28  40  40  40  60  60  60  60  60  60  60  60  60  55 
29  40  40  40  40  40  40  40  40  40  40  40  40  40 
30  40  40  40                             40 
30  40  40  60  40  40  60  60  40  80           51 
34  100  90  100                             97 
34  90  60  60                             70 
36  150  200  100                             150 
37  60  40  40  40  40  40  40  40  40  40  40  40  42 
37  50  40  40                             43 
40  40  80  60  40  80  60  40  80  60  40  80  60  60 
40  40  40  40                             40 
41  90  100  80                             90 
41  40  40  60                             47 
42  40  80  150                             90 
44  50  60  40  40  40  40  40  40  40  40  40  40  43 
44  90  100  90  40  40  60  40  40  60  40  40  60  58 
44  40  40  60                             47 
44  40  80  60  40  80  40  60  80  60           60 
44  60  40  60  60  40  60  80  40  80           58 
45  50  50  40  40  40  40  40  40  40  40  40  40  42 
46  40  40  40  40  40  60  40  40  60  40  40  60  45 
46  40  80  60  40  80  60  40  80  60           60 
47  80  40  90  40  80  60  40  80  60  40  80  60  63 
47  90  90  80                             87 
48  40  50  40                             43 
49  80  80  90  40  40  40  40  40  40  40  40  40  51 
49  60  40  40  40  40  40  40  40  40  40  40  40  42 
49  80  70  80  60  60  40  60  60  40  60  60  40  59 49  80  80  90                             83 
50  40  40  40                             40 
51  60  80  40                             60 
53  80  90  40  40  40  40  40  40  40  40  40  40  48 
53  60  40  40  40  40  40  40  40  40  40  40  40  42 
53  60  80  60                             67 
54  100  90  70  40  40  40  40  40  40  40  40  40  52 
54  40  40  30                             37 
55  100  100  110  40  90  60  60  90  80  40  90  60  77 
56  60  60  40  40  40  40  40  40  40  40  40  40  43 
56  60  90  40  60  100  60  60  100  60  80  100  60  73 
58  80  80  90                             83 
59  40  40  80                             53 
61  110  110  110  40  80  60  40  80  60  40  80  60  73 
61  100  40  100  40  40  40  40  40  40  40  40  40  50 
63  60  50  60  80  90  80  80  90  80  80  90  80  77 
66  110  100  60                             90 
66  80  90  90                             87 
68  80  80  60  40  80  60  40  80  60  40  80  60  63 
68  100  100  100                             100 
70  100  100  100                             100 
70  40  60  40                             47 
71  40  60  40                             47 
74  60  80  90  40  40  60  40  40  60  40  40  60  54 
75  100  90  80                             90 
76  120  110  110  120  150  110  60  80  60  110  100  90  102 
79  60  40  40                             47 
80  120  100  100  90  100  90  90  100  100  90  100  100  98 
80  90  100  80  100  100  90  120  100  110  80  60  80  93 
82  90  40  80                             70 
83  110  100  90  120  120  110  120  100  100           108 
90  60  80  80  40  80  60  40  80  60  40  80  60  63 
90  120  120  120                             120 
96  150  130  150  100  100  100  120  100  120  inv  inv  inv  119 
97  80  100  80  80  100  80  60  100  60  60  100  80  82 
99           80  100  80  100  100  100  80  100  100  93 
100  100  100  90                             97 
101  80  70  70                             73 
102  90  90  60                             80 
103  100  100  100  80  80  80  120  80  120  80  90  80  93 
103  100  100  100                             100 
103  180  200  180                             187 
105  180  180  180  180  180  180  150  150  150           170 
111  120  120  100  180  200  180  120  120  100  150  180  150  143 
112  100  100  80  100  100  80  80  90  40  60  90  40  80 
114  120  110  120  100  100  90  150  150  150  120  100  120  119 
117  120  120  100                             113 
119  120  100  120                             113 120  150  160  150                             153 
123  100  100  100                             100 
125  120  180  150  120  120  150  100  100  120  100  120  120  125 
125  120  120  150  120  150  150  120  120  150           133 
126  100  100  80  100  100  100  100  100  80           96 
133  150  150  180                             160 
134  90  90  80  110  120  150  150  300  180  250  300  200  168 
136  100  100  90  100  100  90  100  100  100           98 
138  200  210  200                             203 
147  200  250  200  120  120  120  180  180  180  180  200  180  176 
152  150  180  200  120  120  150  120  180  180           156 
155  200  250  200  300  300  200  180  200  120  300  400  200  238 
155  220  190  180                             197 
158  120  120  120  150  150  130  150  120  150           134 
160  180  160  150                             163 
162  150  180  180  150  180  150  150  180  180           167 
163  200  210  200                             203 
166  150  150  180  200  180  150  200  180  150  200  300  300  195 
166  250  190  180                             207 
168  200  300  300  400  400  400  400  400  400  400  400  300  358 
173  180  400  200  400  400  400  400  400  300  400  400  300  348 
174  400  300  300  400  300  400  300  300  300           333 
176  300  400  300  400  400  300  400  400  300  400  400  200  350 
181  220  210  180                             203 
194  180  250  300  400  400  200  400  400  200  400  400  300  319 
196  300  250  300  300  300  200  300  250  300           278 
204  180  200  180  180  180  180  120  120  120  250  300  200  184 
218  400  400  400  300  300  200  300  300  300  300  300  300  317 
226  300  300  200                             267 
278  400  400  300  300  400  400  300  400  300           356 
293  300  400  400  400  400  400  300  400  400           378 
376  400  400  400  300  400  300  400  400  300           367 
383  400  400  300  400  400  300  400  400  400           378 
396  400  400  400                             400 
400  400  400  400  400  400  400  400  400  400  400  400  400  400 
425  400  400  400  400  400  400  400  400  400  400  400  400  400 
450  400  400  400  400  400  400  400  400  400  400  400  400  400 
463  400  300  400  400  300  400  400  300  300           356 
470  400  400  400                             400 
490  400  400  400                             400 
 
Table S4. AST serum raw data. R1, R2, and R3 refer to Reader 1, Reader 2, and Reader 3, 
respectively. Paper Test A–D refers to 4 independent tests used to measure the same sample. Blank cells indicate that an insufficient volume of serum was available for all repeats. Inv = 
result was invalid due to sample hemolysis.   
 
 
Total Manufacturing Equipment &  
Personnel 
   
 
$0.0049 
     
Consumable     
Whatman Chromatography Paper    $0.0025 
Wax for wax printer    $0.0008 
Laminate Coating    $0.0005 
Adhesive (Unitak 131)    $0.0004 
Filter Membrane    $0.0250 
Foil-lined Pouch (100 devices/pack)    $0.0075 
Dessicant (1 pack/100 devices)    $0.0075 
Reagents (Enzymes, Chemistry, etc)    $0.0225 
Total Consumable     $0.0667 
     
Total Cost     $0.0715 
 
Table S5.  Cost Per Device Estimate of Paper-based Transaminase Test. Manufacturing costs are 
based on estimated infrastructure and personnel costs for India (costs for similar manufacturing 
in the US would be 2-3X higher). Consumable pricing based on cost of materials currently being 
incurred at the research level and adjusted for lower prices based on volume discount. 
Infrastructure costs include building, setting up manufacturing line, etc. 
 